Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE (NASDAQ: BNTX) generates frequent news flow as a global next generation immunotherapy company focused on oncology, mRNA technologies and COVID-19 vaccines. Its updates often cover progress across a diversified oncology pipeline that includes mRNA cancer immunotherapies, next-generation immunomodulators, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cell therapies, as well as developments in its mRNA vaccine programs for infectious diseases.
Investors following BioNTech news can expect regular announcements on clinical trial milestones in major tumor types such as lung, breast, gynecologic, gastrointestinal and genitourinary cancers. Recent releases have highlighted late-stage data readouts and trial initiations for investigational agents like pumitamig (a PD-L1xVEGF-A bispecific antibody co-developed with Bristol Myers Squibb) and gotistobart (a CTLA-4–targeting Treg modulator), including Phase 2 and Phase 3 results in indications such as triple-negative breast cancer and squamous non-small cell lung cancer.
BioNTech’s news stream also includes corporate and financial updates, such as quarterly results, guidance changes, and details of its cash and investment position. The company reports on its COVID-19 vaccine franchise, including launches of variant-adapted vaccines for specific vaccination seasons, and comments on how vaccine market dynamics affect revenues.
Another recurring theme in BNTX news is strategic transactions and partnerships. BioNTech has announced an all-stock acquisition of CureVac N.V. to strengthen its position in mRNA design, delivery formulations and manufacturing, and regularly issues releases on its collaboration with partners including Bristol Myers Squibb, Duality Biologics, OncoC4, Pfizer and others.
This news page aggregates these developments in one place, allowing readers to track BioNTech’s clinical progress, partnership activity, financial disclosures and strategic updates over time.
BioNTech SE (Nasdaq: BNTX) announced a high-level meeting in Marburg aimed at promoting sustainable vaccine manufacturing within the African Union. This initiative, led by the kENUP foundation, includes distinguished participants such as the President of Senegal and the Director General of the WHO. Public statements will occur on February 16, 2022, followed by a digital press conference detailing BioNTech's vaccine manufacturing efforts in Africa. This meeting underscores the company's commitment to expanding its vaccine production capabilities.
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced plans to extend a rolling submission to the FDA to amend the Emergency Use Authorization for their COVID-19 vaccine, targeting children aged 6 months to 4 years. Ongoing trials are evaluating a three-dose regimen, with data expected in early April, aimed to enhance protection amidst the Omicron surge. The study involves around 8,300 children and is supported by an independent Data Monitoring Committee, underscoring the vaccine's tolerability and potential efficacy.
On February 1, 2022, Pfizer and BioNTech announced submitting data to the FDA for amending the Emergency Use Authorization (EUA) of their COVID-19 vaccine to include children aged 6 months to 4 years. The initial submission seeks authorization for two 3 µg doses, with plans for a third dose in the future. Over 10.6 million children in the U.S. have contracted COVID-19, with a notable increase in hospitalizations among children under 4. If approved, this vaccine would be the first for this age group, addressing a critical public health need.
Pfizer and BioNTech have initiated a rolling submission to amend the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include children aged 6 months to 4 years, at the request of the FDA. This application seeks authorization for two 3 µg doses as part of a planned three-dose series. With over 10.6 million pediatric COVID-19 cases in the U.S., this vaccine could be the first available for children under 5. The companies aim to submit additional data for a third dose in the coming months, enhancing protection against current and future variants.
Pfizer and BioNTech have initiated a clinical trial for an Omicron-based COVID-19 vaccine candidate aimed at healthy adults aged 18 to 55. The study will enroll up to 1,420 participants across three cohorts, evaluating different regimens of the current vaccine versus the Omicron candidate. Senior officials stress the importance of preparing for potential waning effectiveness of current vaccines. The companies continue to expect production of four billion doses in 2022, regardless of the adaptation requirements.
Pfizer and BioNTech have commenced a clinical trial for an Omicron-based COVID-19 vaccine, evaluating safety and immunogenicity in 1,420 healthy adults aged 18-55. This study will assess various dosing regimens of the existing vaccine alongside the Omicron variant candidate. With the ongoing risk of waning vaccine effectiveness against emerging variants, the companies aim to provide longer-lasting protection. The trial is part of an extensive strategy to address evolving COVID-19 challenges while maintaining production capabilities of the current vaccine.
BioNTech and InstaDeep have developed an Early Warning System (EWS) for detecting high-risk SARS-CoV-2 variants using AI. This scalable system combines structural modeling of the viral Spike protein with predictive analytics, identifying over 90% of WHO-designated variants two months in advance. The EWS can evaluate new variants in minutes and has detected variants like Omicron on the same day their sequences were uploaded. The study, available on BioRxiv, aims to enhance preparedness against future COVID-19 variants.
BioNTech and Crescendo Biologics have announced a multi-target discovery collaboration to develop novel immunotherapies for cancer treatment. BioNTech will have exclusive worldwide development and commercialization rights to the therapies generated from this partnership. Crescendo will receive an upfront payment of $40 million, along with potential milestone payments exceeding $750 million, plus royalties on global net sales. The collaboration will leverage Crescendo's Humabody® VH platform, known for high-affinity binding and enhanced tissue penetration, over an initial term of three years.
Pfizer and BioNTech have announced a collaboration to develop an mRNA-based vaccine for shingles, targeting the herpes zoster virus. This partnership marks their third collaboration in infectious diseases, building on their previous successes with COVID-19 and influenza vaccines. Under the agreement, BioNTech will receive $225 million upfront, while Pfizer will secure $25 million for its proprietary antigen sequences. Clinical trials are set to begin in the second half of 2022, with cost-sharing and profit-sharing on potential vaccine sales.
BioNTech and Pfizer announced a collaboration to develop a potential mRNA-based vaccine for shingles, targeting the herpes zoster virus (HZV) that affects one in three individuals in the U.S. The partnership, their third in infectious diseases, aims to leverage BioNTech’s mRNA technology alongside Pfizer’s antigen technology. Under the agreement, BioNTech will receive $225 million upfront and can earn up to $200 million in future milestone payments. Clinical trials are expected to commence in the latter half of 2022, with Pfizer holding global commercialization rights.